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Summary
OBJECTIVE: The methods used to diagnose and classify
ovarian cancer have changed over the past decade. We
used hospital registry data to assess the incidence, treat-
ment durations and hospital costs of ovarian cancer in
Switzerland.
METHODS: We carried out a retrospective analysis of a
hospital registry covering all inpatient care episodes in
Switzerland between 1998 and 2012. Ovarian cancer in-
cidence was assessed by identifying patients with a first
ovarian cancer diagnosis as the main reason for hospital
stay after an event-free period. We assessed the duration
and cost of ovarian cancer treatment sequences as well
as the evolution of hospital patient volume over time.
RESULTS: The average age-adjusted incidence rate was
14.6 per 100,000 women per year between 2004 and
2012. This rate is substantially higher (+35.5%) than the
corresponding rate published by the National Institute for
Cancer Epidemiology and Registration (NICER). Hospital
patient volume was low in most cases, with more than
40% of patients treated in hospitals with fewer than 20
cases per year. However, the share of patients treated in
hospitals with more than 30 cases per year has increased
substantially since 2009.
CONCLUSIONS: We found a substantial difference be-
tween the ovarian cancer incidence estimate based on
hospital registry data and the corresponding estimate by
NICER. The reasons for this substantial difference should
be carefully explored. A case-wise comparison could de-
termine whether the difference is due to over- or under-re-
porting in one of the two registries. The low ovarian can-
cer patient volume in many hospitals is in conflict with the
numbers required for certified specialised cancer centres.
The recent increase in patient volume in specialised can-
cer centres, however, might reflect a growing understand-
ing of the needs and requirements of comprehensive can-
cer care.
Keywords: ovarian cancer, epidemiology, prevalence, in-
cidence, hospital registry, cancer registry, hospital patient
volume, specialised care, cost, Switzerland
Introduction
Ovarian cancer is one of the most common cancers in
women, and the most aggressive form of cancer of the fe-
male reproductive system. The age-adjusted yearly inci-
dence rate was estimated at 13.1 per 100,000 European
women in 2012 [1]. Most women are diagnosed at ad-
vanced FIGO stages, when the chance of survival for 5
years is less than 30% [2].
Switzerland has one of the most expensive and generous
healthcare systems, with universal access and a virtual ab-
sence of waiting times [3]. However, Switzerland has an
excessive number of hospitals for its population and ge-
ography [4]. Among the (in 2012) 174 acute care hospi-
tals (for a population of 8.0 million) [5], many have small
case volumes for specialised treatments. The low degree of
specialisation of many hospitals treating ovarian cancer pa-
tients has been criticised previously. Surgical staging was
found to often be incomplete when performed in smaller
centres with few patients [6].
The National Institute for Cancer Epidemiology and Reg-
istration (NICER) has reported an average age-adjusted in-
cidence rate of 10.8 per 100,000 women in ovarian can-
cer over the period from 2008 to 2012 [7]. A study from
the canton of Vaud based on data collected by the Cancer
Registry in the period 1974 to 1988 found an even lower
age-adjusted incidence rate of 9.6 [8]. However, this result
may underestimate the true ovarian cancer prevalence in
Switzerland as the cancer registry data are based on vol-
untary information on new cases from clinicians. Only the
new cancer registration law, which will take effect from
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2020, requires all cantons to establish cantonal cancer reg-
istries and all healthcare providers to report incident cancer
cases to these registries. Little is known about the changes
in and the quality of the treatment provided in Swiss hospi-
tals over the past decade. Patient volume per hospital is an
additional measure of quality, particularly with respect to
expert specialisation, presence of a study nurse, data man-
agement and opportunities for a patient to receive the latest
drugs via an international trial.
For the first time in Switzerland, the Swiss hospital registry
is used in this study to examine the incidence of ovarian
cancer as well as its treatment episodes and cost [9]. Sur-
prisingly, this rich and highly representative hospital reg-
istry has up to now been rarely used in studies in the field
of epidemiology, in health services research, and in health
economics [10].
This study assesses the incidence of ovarian cancer in
Switzerland between 2004 and 2012 based on a hospital
registry covering all inpatient care episodes. It further de-
scribes recent trends in the inpatient treatment of ovarian
cancer regarding the type and duration of treatment, the
type of treating hospital and the yearly hospital patient vol-
ume. Finally, it assesses the costs of single inpatient care
stays and of the whole inpatient treatment sequence of an
ovarian cancer patient.
Materials and methods
Data
Our main data source was the hospital registry provided by
the Swiss Federal Statistical Office [9]. The registry con-
tains detailed information on all patients hospitalised since
1998 (socio-demographics, diagnoses, treatments etc.). A
unique patient identification number tracks patients over
time and across treatment sites. The registry has a virtually
complete coverage of all inpatient treatments as participa-
tion is mandatory [11]. The coding quality of the registry is
high in acute care hospitals, particularly since the introduc-
tion of a diagnosis-related group payment system (Swiss-
DRG) in 2012. The hospital registry includes information
on the in-hospital mortality but not out-of-hospital mortal-
ity, which limits the possibility of assessing the effect of
treatment on mortality.
Identification of ovarian cancer patients
Ovarian cancer patients were identified by the ICD-10
code C56 (malignant neoplasm of the ovary) as the main
diagnosis in the hospital registry. According to the coding
manual, the main diagnosis should correspond to the diag-
nosis dominating treatment costs [12]. We did not consider
cases with C56 as a secondary diagnosis as incident cases.
These cases are likely to include patients previously hospi-
talised with an ovarian cancer main diagnosis.
Incidence calculation
We calculated the yearly age-adjusted ovarian cancer in-
cidence rate per 100,000 women. The number of incident
cases was determined by the number of new cases with
ovarian cancer as the main diagnosis in a given year. A
new case was defined as a patient not diagnosed with ovar-
ian cancer in a preceding event-free period of predeter-
mined duration. The duration of this period was deter-
mined by increasing the number of event-free years until
the probability of a previous ovarian cancer diagnosis fell
below a threshold of 1.5%. We did not choose an even low-
er threshold because some cases may be the result of data
input errors or misclassifications (supplementary fig. S1 in
appendix 1).
The age adjustment compensates for demographic changes
in the population and allows the international comparison
of the incidence rates. We used the direct age adjustment
method also applied by NICER [13]. Patients identified as
out-of-pocket payers were considered as foreign residents
coming to Switzerland for medical treatment. We excluded
them from the incidence rate calculation as all Swiss resi-
dents are covered by mandatory health insurance.
Our procedure implicitly assumes that all women with
ovarian cancer had at least one inpatient care episode with
ovarian cancer as main diagnosis. This assumption seems
justified in view of the severity of the disease and the stan-
dard of care in Switzerland.
Identification of treatment sequences
We constructed ovarian cancer treatment sequences for all
incident patients in order to assess the overall duration and
cost of inpatient treatments for each patient. The treatment
sequence of a single patient links all her inpatient stays
with ovarian cancer as the main or secondary diagnosis.
The length of the sequence was calculated as the time from
the first to the last of these inpatient stays. The beginning
of the treatment sequence was identified by the first inpa-
tient stay with an ovarian cancer main diagnosis. The end
of the treatment sequence was unfortunately less clear, ex-
cept for patients who passed away in the hospital. In order
to define the end of the treatment sequence, we therefore
introduced a second inpatient-event-free period of three
years after the last ovarian cancer stay of the treatment se-
quence. Women who were alive at the end of the treatment
sequence may have been either cured from ovarian cancer,
have continued to have treatment in an ambulatory setting
or abroad, or have passed away out of hospital. Some pa-
tients may seek inpatient treatment after the three-year pe-
riod. However, the incidence of these cases is likely to be
so low that it can be neglected.
Inpatient treatment
In most cases, the beginning of a classical ovarian cancer
treatment starts with an operation. We therefore assessed
whether patients underwent an ovarian cancer-specific sur-
gical treatment at their first hospitalisation with ovarian
cancer as the main diagnosis. The types of treatments pro-
vided to patients are coded in the hospital registry with the
Swiss Classification of Medical Procedures (CHOP) [14].
The following CHOP-codes were used to identify an ovar-
ian cancer-specific surgical treatment: 65 (surgery of the
ovaries), 54 (other surgery in the abdomen) and 68 (other
incisions and excisions of the uterus). All treatments oth-
er than these CHOP codes were classified as other treat-
ments. A minority of patients with advanced FIGO stage
IIIC or IV disease and poor ECOG status are initially treat-
ed not by surgery, but by neoadjuvant chemotherapy. A
specific coding for such chemotherapy does not exist, so
all chemotherapy treatments are identified by the CHOP
code 9925XX.
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Hospital patient volume
Hospital case volume is an increasingly important indica-
tor of quality of care, as specialised, comprehensive can-
cer centres have been shown to have a direct impact on the
outcome for ovarian cancer patients [6, 15]. Therefore, we
calculated the hospital case volume for patients with ovar-
ian cancer as the main diagnosis for each individual hos-
pital and assigned the hospitals to four volume categories:
fewer than 10 patients/year, 10–19 patients/year, 20–29 pa-
tients/year, 30 or more patients per year. We then assessed
whether patient volumes were associated with hospital size
and how the share of ovarian cancer cases in individual
hospitals changed over time.
Inpatient care costs
Inpatient healthcare costs were calculated using prices for
the year 2012, as the new payment system (SwissDRG)
was first introduced that year. The average treatment cost
of a hospital stay was calculated by multiplying the Swiss-
DRG cost weights with the average cost of an acute care
inpatient treatment in 2012. The cost of treatment se-
quences was calculated by adding the individual costs of
the cases identifying the sequence.
Data analysis
The results are presented in terms of means and standard
deviations (SDs). Incidence is given as the number of cases
per 100,000 per year. T-tests were used to compare differ-
ences in mean across hospital types. All analyses were per-
formed with STATA 14.
Results
Incidence of ovarian cancer
The duration of the event-free period necessary for the in-
cidence calculation was determined at six years based on
the data from 2010 to 2012 (fig. 1). The number of inci-
dent ovarian cancer cases could thus be assessed for the
2004-2012 period. The yearly average number of incident
ovarian cancer cases was 753.1 (SD 31.8), which includ-
ed an average of 28.2 (SD 7.2) foreign residents (supple-
mentary fig. S2 in appendix 1). The average age-adjusted
ovarian cancer incidence rate per 100,000 women (without
foreign residents) was 14.6 patients over the 2004-2012
period and decreased to 13.8 in 2012 (fig. 2). The mean age
of patients newly diagnosed with ovarian cancer was 62.17
years (SD 15.13) (fig. S3).
Treatment sequences
The average length of an ovarian cancer treatment se-
quence was 134.0 days (SD 294.2) and consisted of an av-
erage number of 2.06 (SD 2.6) hospital stays. The length of
a single hospital stay with ovarian cancer as the main diag-
nosis decreased from 11.2 days (SD 11.2) in 2002 to 10.9
(SD 11.8) days in 2012. We did not find any statistically
significant differences in the length of single hospital stays
after ovarian cancer surgery between specialised hospitals
(more than 30 cases per year) and non-specialised hospi-
tals (fewer than 30 cases per year). Furthermore, we found
no statistically significant differences in the length of treat-
ment sequences or in the number of main diagnosis ovari-
an cancer hospital stays with surgery (table 1).
Hospital case volume
Ovarian cancer hospital patient volume was low in most
Swiss hospitals, with over 80 institutions treating fewer
than 10 patients per year in 2012. Therefore, up to 2012,
most ovarian cancer patients were treated in hospitals with
a case volume of less than 30 ovarian cancer patients per
Figure 1: Length of event-free period and the percentage of
patients with ovarian cancer before event-free period. The fig-
ure shows the percentage of patients with ovarian cancer (OC) be-
fore event-free periods of different lengths. The longer the event-
free period, the lower the percentage of patients identified with
ovarian cancer before the event-free period.
Figure 2: Age-adjusted incidence rate of ovarian cancer as the
main diagnosis from the hospital registry compared to NICER
cancer registry data. The figure illustrates the age-adjusted inci-
dence rate of ovarian cancer per year. The blue lines show the in-
cidence calculated with MS, while the dark line is the incidence
found by NICER.
Table 1: Comparison between specialised and non-specialised hospitals.
Specialised hospi-
tals
Non-specialised hospi-
tals
Difference between
hospital types
95% confidence interval
Length of overall treatment episode (days: mean, SD) 106 (242) 130 (302) −23.8 −6.99 to 54.49
Length of hospital stay with OC main diagnosis and surgery (mean,
SD)
13 (12) 12 (10) 1.1 −2.47 to 0.25
Number of hospital stays with OC main diagnosis and surgery
(mean, SD)
4.1 (6) 4 (4) 0.1 −0.74 to 0.47
SD = standard deviation
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year despite the growing evidence that this leads to poorer
outcomes (fig. 3).
Importantly, the number of specialised centres or compre-
hensive cancer centres treating 30 or more ovarian cancer
patients per year has only increased since 2009. The share
of ovarian cancer cases by hospital case volume category
was dominated by hospitals with fewer than 30 cases per
year (fig. 4). While before 2009 fewer than 20% of sur-
gically treated patients were treated in specialised centres,
this proportion has since increased to almost 50% in 2012,
probably due to the increasing number of certified cancer
centres.
Inpatient care costs
The average cost of a single hospital stay of an ovarian
cancer patient was 16,642 CHF (Swiss Francs) in 2012.
The cost increased with hospital case volume, from 13,877
CHF in hospitals with 0 to 9 cases per year to 18,346
CHF in hospitals with 30 or more cases per year. The av-
erage cost of a hospital stay with a surgical intervention
was 22,188 CHF, and the average cost of a stay with
chemotherapy was 10,297 CHF. The cost of hospital stays
with ovarian cancer as the main diagnosis is slightly higher
than the average cost of hospital stays by patients with
other cancers requiring surgical interventions: lung cancer
(C34.9; CHF 11,249), breast cancer (C50.9; CHF 11,536),
prostate cancer (C61; CHF 13,778) and bowel cancer
(C18.9; CHF 11,783). The average cost of a complete
ovarian cancer inpatient treatment sequence over the pe-
riod 2004–2009 was CHF 22,246 (calculated at 2012
prices).
Figure 3: Number of hospitals by ovarian cancer case volume
by year. The figure illustrates the evolution of each hospital case
volume category over time by showing the number of hospitals in
each defined category.
Figure 4: Share in yearly case volume by hospital case vol-
ume category. The figure shows the share of each hospital vol-
ume category and its evolution over time.
Discussion
We find an average age-adjusted ovarian cancer incidence
rate of 14.6 cases per 100,000 women per year between
2004 and 2012. This rate is substantially higher (+35.5%)
than the corresponding rate of 11.3 per 100,000 women per
year reported by NICER for the same period. Both data
sources show a slight decrease in ovarian cancer incidence
from 2004 to 2012. Furthermore, we find that a consider-
able proportion of ovarian cancer patients were treated in
hospitals with a low hospital case volume. Many patients,
therefore, may be being treated in hospitals which are not
sufficiently specialised.
Although our estimate of the ovarian cancer incidence rate
is substantially higher than the previous estimate for
Switzerland, it is within the range of rates reported for
other countries. According to EUCAN [16], the ovarian
cancer incidence rates in large European countries varied
from 16.0 in the UK to 13.3 in Italy, 10.7 in France and
10.2 in Germany in 2012. The highest rate reported in Eu-
rope was 18.9 for Latvia, and the lowest was 4.2 for Al-
bania. Our results indicate that part of these differences
in incidence rates may be due to differences in the under-
lying data sources. The reasons for these substantial dif-
ferences should be carefully explored. A case-wise com-
parison could, for example, detect whether the difference is
due to over- or under-reporting in one of the two registries.
A number of reasons may have led us to under- or overes-
timate the true ovarian cancer incidence rate. Underestima-
tion may be due to: (1) ovarian cancer cases not diagnosed.
(2) Patients diagnosed with ovarian cancer but treated ex-
clusively in an outpatient setting. (3) We excluded patients
first diagnosed with ovarian cancer as a secondary diagno-
sis from the incident cases because this diagnosis is likely
to be a consequence of other diseases. However, some of
these cases might not have been the consequence of oth-
er cancers and should thus have been considered among
the incident ovarian cancer cases. Overestimation of inci-
dent cases may be primarily due to including cases first
diagnosed before the event-free period of six years. How-
ever, even extending the event-free period to eight years
would only decrease the percentage of patients with ovar-
ian cancer before the event-free period by 1.06% (see fig.
1). Moreover, the assumption of an event-free period of six
years appears sensible from a clinical point of view.
The high number of ovarian cancer patients treated in hos-
pitals with a low patient volume casts doubt on the ade-
quacy of the surgical treatments in particular. However, in-
clusion in clinical system therapy trials with the chance to
receive new drugs is also limited. In gynaecological oncol-
ogy, and particularly in ovarian cancer, treatment regimens
are increasingly based not on the organ itself but on its
molecular background. In the past two decades, a plethora
of molecular methods has delivered a multitude of molecu-
lar targets in ovarian cancer. It is a challenge for a subspe-
cialised gynaecological oncologist in a highly specialised
cancer centre to be aware of all new technologies, path-
ways and drugs under development, but this is nearly im-
possible for a private gynaecologist operating in a small
hospital. The standard tumour board involving a patholo-
gist, radiologist, medical oncologist, radiation oncologist
and a gynaecologist might still be present in smaller hos-
pitals. In a larger and more comprehensive centre, how-
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ever, this group is often enriched by a gynaecological on-
cologist, a geneticist, a gynaecological cancer nurse, study
nurses and case management, who aim to incorporate pa-
tients into trials of important new drugs with additional
benefits, or to improve the recovery phase and lower the
morbidity of patients. This might explain the higher costs
found in highly specialised cancer centres.
Our study illustrates how the hospital registry can be em-
ployed to generate relevant information on the epidemiol-
ogy and treatment of diseases in Switzerland. This exam-
ple may be extended to other diseases. However, hospital
registry data cannot match cancer registries with regard to
diagnostic information on the type of disease or the out-
comes of patients. It thus provides complementary infor-
mation to the cancer registries and could represent a key
component of a big data network which monitors diseases,
treatments and outcomes.
Conclusion
This analysis identified several issues which may be of
concern for the optimal care of ovarian cancer patients
in Switzerland and which probably also reflect the situa-
tion in other European countries: (1) cancer registry data
are not representatively available; (2) half of patients were
treated by doctors (specialised or not) in centres with a
workload of less than 30 ovarian cancer patients per year.
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Appendix 1
Supplementary figures
Figure S1: Overview of exemplary ovarian cancer cases and
inpatient treatment episodes in MS.The figure illustrates how
single inpatient care events are combined into inpatient treatment
sequences of ovarian cancer patients. Exemplary patients illus-
trate some of the many possible treatment sequences: Patient 1
has only one hospital stay in 2003. This stay is coded with an
ovarian cancer main diagnosis and the patient dies in hospital. Pa-
tient 2 is identical to patient 1 but is released alive. Patient 3 is first
treated in 2003 with an ovarian cancer main diagnosis and then for
a second time in 2004 with an ovarian cancer secondary diagno-
sis. In 2005 she is hospitalised with a diagnosis not related ovarian
cancer and released alive. Patient 6 is hospitalised one time in
2003 and two times in 2004 with a non-ovarian cancer diagnosis.
The first stay with ovarian cancer main diagnosis is recorded in
2006 and is followed by two more hospitalisations with ovarian
cancer diagnosis. This patient is again hospitalised in 2008 with a
non-ovarian cancer diagnosis is released alive.The identification of
incident cases is illustrated by patients 4 and 5: The event-free du-
ration is assumed to be four years (1998-2001). Patient 4 had an
inpatient care event in 2001 which was, however, not ovarian can-
cer related. The patient’s ovarian cancer main diagnosis in 2004
will therefore be considered among the incident cases in this year.
In contrast, patient 5 had a first ovarian cancer main diagnosis in
the year 2000. Therefore, her second hospitalisation with an ovari-
an cancer main diagnosis in 2002 is not considered among the in-
cident cases in 2002.
Figure S2: Incidence as number of new cases per year
(2004-2012). The figure illustrates the number of new ovarian can-
cer cases per year. The blue lines show the incidence of new cas-
es calculated with MS, while the dark line is the incidence of new
cases found by NICER.
Figure S3: Age distribution of incident ovarian cancer cases
(2004–2012). The figure depicts the age distribution of women di-
agnosed for the first time with an ovarian cancer.
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